HHumana sells health insurance paid for by government programs, chiefly Medicare Advantage plans that private insurers run for Americans 65 and older in place of traditional Medicare. It ranks among the largest Medicare Advantage insurers in the country and also runs Medicaid plans for low-income families in several states. Its CenterWell business operates senior primary care clinics, a mail-order pharmacy and home health services, so many members get care from a company the insurer owns. Medicare and states pay Humana a set monthly amount per member, and it keeps the difference between those payments and members' medical costs. Humana was founded in 1961 as a nursing home company and is based in Louisville, Kentucky.
Work here?Claim your company
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
Louisville, KY
Founded
1961
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$9.4B
Above
Industry Average
Funded Over
5 Rounds
Healthcare stocks have returned 33.2% over the past six months, beating the S&P 500 by 26.1 percentage points. Even so, StockStory says new venture-backed competition means only a few companies will thrive long term. It rates Humana (NYSE:HUM) a buy. The health insurer's revenue grew 15.1% a year over the last two years to $145.8 billion, and its return on invested capital (ROIC) is 32.9%. Its shares trade at $411.09, or 33.7 times forward earnings, giving it a market value of $49.77 billion. It would avoid two stocks. West Pharmaceutical Services (NYSE:WST), valued at $28.74 billion, has seen revenue growth of 4.8% a year over five years and a 4.5 percentage point fall in adjusted operating margin. Zoetis (NYSE:ZTS), valued at $32.94 billion, has grown sales 2.7% a year over two years, and sales are projected to fall 1.2% over the next 12 months.
A Simply Wall St screen flags three large US health insurers as well placed if interest rates stay higher for longer: Elevance Health, CVS Health, and Humana. The screen favours quality value companies with solid balance sheets and dependable cash flow. Elevance Health has a market value of about $95.1 billion. Its Health Benefits unit brings in about $170.4 billion of revenue, and Carelon's CarelonRx and Carelon Services add about $45.1 billion and $30.1 billion. CVS Health is valued at about $119.5 billion, with Health Services revenue of about $200.5 billion. It took a $1.1 billion charge tied to Medicare and Individual Exchange businesses and a $1.2 billion restructuring charge for store closures. Humana, valued at about $50.7 billion, draws about $139.7 billion from insurance and $24.7 billion from CenterWell. Regulators are sharpening their focus on its risk adjustment data and prior authorization standards.
US insurers including UnitedHealth and Humana are cutting benefits for older clients and raising prescription drug costs for 2027, weeks before the midterm elections. Both insurers scrapped hundreds of plans and tightened coverage as older voters began choosing their plans. UnitedHealth and Humana raised maximum out-of-pocket costs by 11% and 8% respectively, according to investment bank Leerink. Both raised prescription drug coverage costs by about 30%. The changes affect 35 million Americans on Medicare Advantage plans, and the two firms hold about 46% of that market. The changes should help insurers' profits. UnitedHealth's healthcare division operating margin rose to 3.3% from 2.1% a year earlier, and Humana's shares are up 57% this year.
Humana shares surged 15% after the insurer announced 95% of its Medicare Advantage members will be in plans rated four stars or higher for 2027, up from just 20% a year ago. The result significantly exceeded J.P. Morgan analysts' expectations of 60% to 70%. Plans with four-star ratings or higher qualify for government bonus payments worth billions across the industry. The industry average for 2027 stands at roughly 71%. However, these ratings will determine bonus payments for 2028, not 2027. The improved ratings are particularly significant given Humana's thin margins. The company's EBIT margin has declined from 4.3% in 2023 to 2.3% on a last-twelve-months basis. Meanwhile, competitors moved in the opposite direction. UnitedHealth's four-star share is estimated to fall to approximately 67% from 81%, whilst CVS Health's drops to around 70% from 84%. CVS shares declined roughly 3%.
The health insurance industry may have recovered from high medical costs, with analysts predicting strong growth through 2030. Morningstar forecasts 16% annual earnings per share growth for major insurers, above the industry's typical low-double-digit target. Health insurers are improving profitability by raising rates to cover increased medical utilisation. UnitedHealth Group reported over $5 billion in second-quarter net income, with its medical care ratio falling to 86.7% from 89.4% year-over-year. The outlook also improved for pharmacy benefit management operations at companies like UnitedHealth, CVS Health, and Cigna. Despite increased regulatory scrutiny, the "big three" PBMs maintain strong competitive positions. Third-quarter earnings reports next month should provide further clarity on the industry's financial health.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
10,001+
Company Stage
IPO
Headquarters
Louisville, KY
Founded
1961
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs